Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use

First-In-Class Drug’s List Price Is $89,500 Per Year

Executive Summary

Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label. 

You may also be interested in...



All Eyes On Bristol's New Launches

Bristol Myers Squibb has launched three new first-in-class drugs this year – Opdualag, Camzyos and Sotyktu – and investors are closely watching the early momentum.

BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu

Chief commercialization officer Chris Boerner said BMS plans to replace Otezla as the oral standard of care for moderate-to-severe psoriasis with Sotyktu (deucravacitinib); its list price is about 40% higher than Amgen’s product.

Bristol’s New Products Meet Early Launch Expectations

Sales rose significantly for Reblozyl and for Abecma and Breyanzi, despite manufacturing challenges for the two cell therapies. Newly approved Opdualag and Camzyos are off to encouraging starts.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel